During the last 3 years we implemented three full portfolio (102 SKUs) evaluations in the SEA markets, including Thailand, Vietnam, Malaysia, Indonesia, Singapore, Philippines and Taiwan. We delivered a fully exhaustive evaluation of regulatory feasibility, commercial interest, pricing strategy, competition, plus a complete list of potential partners for distribution in the different markets. This information allowed our clients to define a entry strategy and progress in their global expansion… Show more During the last 3 years we implemented three full portfolio (102 SKUs) evaluations in the SEA markets, including Thailand, Vietnam, Malaysia, Indonesia, Singapore, Philippines and Taiwan. We delivered a fully exhaustive evaluation of regulatory feasibility, commercial interest, pricing strategy, competition, plus a complete list of potential partners for distribution in the different markets. This information allowed our clients to define a entry strategy and progress in their global expansion in APAC. Show less

•Manage a team of 7 highly qualified professionals, plus 5 external local partners, in supporting the international expansion of more than 50 customers in APAC, Europe, Mena, and LATAM. Our experts work as an external business developer team identifying, contacting, negotiating, and closing agreements of in-licensing, out-licensing, distribution, technology transfer, M&A, and fundraising. Despite the COVID crisis, the company is growing in new projects by over 80% in 2020 versus… Show more •Manage a team of 7 highly qualified professionals, plus 5 external local partners, in supporting the international expansion of more than 50 customers in APAC, Europe, Mena, and LATAM. Our experts work as an external business developer team identifying, contacting, negotiating, and closing agreements of in-licensing, out-licensing, distribution, technology transfer, M&A, and fundraising. Despite the COVID crisis, the company is growing in new projects by over 80% in 2020 versus 2019.•Company founder and since 2015 GM with full P&L responsibility in Europe and Asia. Building the commercial/ administrative structure of the company, including selection, training, and leading a highly skilled team of junior and senior executives•Full redefinition of the operational areas of the company by creating the #ophthalmic, #biosimilar, #medicaldevices, and #food supplements specialized divisions. •Build an over 30.000 professional DB of connections belonging to more than 4.000 companies in the Healthcare segment worldwide, at senior levels (BD, GM, regulatory, R&D, commercial/ marketing), fully updated and operational•More than 150 projects developed in the international expansion of innovative products, medical devices, functional food, generics and biosimilars in Asia, Europe MENA and LATAM•Design and execution of several projects focused in finding innovative products in several therapeutics, such as urology, oncology, HIV, Diabetes, Respiratory, Gynecology, and pediatrics for in-licensing in different markets in EU markets, ASEAN and LATAM •Successfully implemented projects focused on finding products with a special value, such as niche #orphandrugs, special combinations of CV generics, generic plus, #biosimilars, and #medicaldevices •Launch/Follow up of core project for an Asian HQ company to enter EU markets opening an affiliate. Show less

Developer of an innovative new methodology to select #biosimilarcandidates considering all the value chain, from #bio-API sourcing, manufacturing, registering, stakeholders, access to market, pricing expectations to company internal portfolio evaluation. Several lectures on biosimilar's commercial developmentStrategic partner of Pharma Synergy in the biosimilar sessions8 written articles in biosimilars 2019Author of the "EU Biosimilars guide 2019"Chairman and lecturer in… Show more Developer of an innovative new methodology to select #biosimilarcandidates considering all the value chain, from #bio-API sourcing, manufacturing, registering, stakeholders, access to market, pricing expectations to company internal portfolio evaluation. Several lectures on biosimilar's commercial developmentStrategic partner of Pharma Synergy in the biosimilar sessions8 written articles in biosimilars 2019Author of the "EU Biosimilars guide 2019"Chairman and lecturer in Pharma Synergy Feb 2020, Pharma Synergy Virtual July 2020, and Bio Pharma Synergy Virtual 2021 Show less

New platform committed to supporting business opportunities exchange within the biotech segment, with a special focus on biosimilars and bio-betters. We handle a more than 260 companies database covering pharmaceuticals developing, manufacturing, commercializing or interested in biosimilars worldwide.

Launch of commercial activities in EU markets with the existing FDF portfolio in Oncology and Infectious Diseases Market entry in Denmark (winning first national tender attended), Spain (winning 4 first national tenders attended), UK (signed agreement with international partner generating first sales in the market), Germany (signing agreement with local partner generating first sales in the country), Italy (signing agreement with international leader to attend all tenders in 2019 just after… Show more Launch of commercial activities in EU markets with the existing FDF portfolio in Oncology and Infectious Diseases Market entry in Denmark (winning first national tender attended), Spain (winning 4 first national tenders attended), UK (signed agreement with international partner generating first sales in the market), Germany (signing agreement with local partner generating first sales in the country), Italy (signing agreement with international leader to attend all tenders in 2019 just after products approval), France (addressing suitable partner and driving negotiations ready to be closed before product approval 2Q19), addressing suitable partners searching for local distribution/out-licensing in Poland, Austria, Belgium, Finland & The NetherlandsDesign of a strategic plan for new products acquisition/production for EU marketsDesign of a portfolio optimal expansion plan to increase revenues in Spain Design of a project to open a fully owned commercial affiliate for the German MarketOpening business opportunities (outlicensing & distribution agreements) in LATAM (Colombia, Chile) and MENA (Saudi Arabia, Irak) Searching and evaluation of M&A opportunities aligned with the strategic plans of Qilu Pharmaceutical in Europe Show less

Consolidate Company Leadership in new geographies. New Services Design: Companies support for global expansion: access to European markets for companies developing products in Natural Health (food and drug). In/out licensing support for EU, US, APAC and LATAMCompany areas of expertise: Product design and development, regulatory strategy (EFSA, EMEA, FDA) in the food and healthcare fields, including border line products, clinical research, in & out product licensing partnering… Show more Consolidate Company Leadership in new geographies. New Services Design: Companies support for global expansion: access to European markets for companies developing products in Natural Health (food and drug). In/out licensing support for EU, US, APAC and LATAMCompany areas of expertise: Product design and development, regulatory strategy (EFSA, EMEA, FDA) in the food and healthcare fields, including border line products, clinical research, in & out product licensing partnering searching and marketing strategy design and developmentCore areas of focus: EU (France, Spain ,Italy, Nordic Countries, East Europe),US, APAC and LATAM Show less

M&A Activities in APAC, LATAM, AF.JV assessment activities in LATAM and APACActivities for opening Affiliates in: Thailand, Indonesia, Malaysia and The PhilippinesOut-licencing activities in GI, GYN, PED, Res, Derma Rx products to US and APACIn-licencing activities with priority in GI, GYN, PED, RES, DIABResponsible for commercial evaluation of Internal R&D projects

Marketing plans and sales objectives supervision and approval for 61 countries in two strategic therapeutic areas (Diabetes and Bone Metabolism) Team member on Diabetes Market Access ProgramMember of the Global Market Team in Bone MetabolismTeam leader of Amaryl M project, a multitask team created to launch combination of Glimepiride and Metformine in 52 countries Considered as best launch of the year in the Intercontinental Region, producing an upside of nearly 7MM€ in… Show more Marketing plans and sales objectives supervision and approval for 61 countries in two strategic therapeutic areas (Diabetes and Bone Metabolism) Team member on Diabetes Market Access ProgramMember of the Global Market Team in Bone MetabolismTeam leader of Amaryl M project, a multitask team created to launch combination of Glimepiride and Metformine in 52 countries Considered as best launch of the year in the Intercontinental Region, producing an upside of nearly 7MM€ in 2.006, reason why the product Amaryl (Glimepiride) was nominated “best Performer 2006” in ITC (intercontinental Region) with sales +17% above budget. Show less

Design and development of the Linea Clasica concept for Mature Portfolio Management (120 million euros). Linea Clasica was a project based on the selection of products suitable for active promotion and after the approval of a business case including external sales force activities and pilot test results, implement a highly innovative and profitable direct market campaign. The project was capable to reduce cost por impact in 60% and considerably increase Business Unit ROI. The campaign… Show more Design and development of the Linea Clasica concept for Mature Portfolio Management (120 million euros). Linea Clasica was a project based on the selection of products suitable for active promotion and after the approval of a business case including external sales force activities and pilot test results, implement a highly innovative and profitable direct market campaign. The project was capable to reduce cost por impact in 60% and considerably increase Business Unit ROI. The campaign, addressing 20.000 Spanish General Practitioners was awarded by PM Pharma with the Aspid Award to the best direct marketing campaign of the year. The project was presented in international Sanofi company forums as one of the most innovative and successful to leverage Base Business activities considered one of the company priorities after the merger with Aventis. Show less

Marketing responsible for Aprovel, antihipertensive blockbuster ranked 2nd in company sales 2.003. Aprovel is a ARB II with significant effect lowering blood pressure and renal protection. Core activities were Marketing Plan design and implementation, KOL management with Cardiogists, Internal Medicine and Primary Care Physicians and Sales Force Effectiveness activities to optimize promotional investments.

Pharma Division start-up and development

Responsible of successful launching of four HIV products in Spain, including the first protease inhibitors

Distribution change from Exclusive Distributors to 86 Direct Sales Force. Team training and bonus scheme development